
Matching FSGS Therapy to Disease Phase, With Astrid Weins, MD, PhD
Sparsentan, B cell therapies, and TRPC6 and APOL1 inhibitors may each fit a different stage and cause of FSGS.
Getting the most from a growing set of therapies for
Weins moderated “Advances in Treatment and Management of FSGS,” an educational symposium at
Where Sparsentan Fits in FSGS Treatment
In April 2026, the
Weins described sparsentan as a supportive therapy that can help in almost any case of podocyte loss, replacing an ACE inhibitor or angiotensin receptor blocker and adding endothelin blockade.
“It is more a therapy that will generally reduce proteinuria more in patients that have adaptive FSGS or are in the later phase of their disease journey,” she said.
B Cell Directed Therapies for Immune-Mediated Podocytopathy
“What really helps the patients acutely, especially in autoimmune mediated podocytopathies, are B cell directed therapies,” Weins said.
She expects a large group of B cell directed or B cell modulating drugs to be approved over the coming months and years, including APRIL and BAFF inhibitors and CD19 and CD20 inhibitors. In her view, these agents matter most in the early, immunologically active phase of FSGS and diffuse podocytopathies.
Most of these trials are still ongoing. Weins said early results look promising and that lessons from
TRPC6 Inhibition and APOL1-Targeted Therapy in FSGS
Weins also pointed to TRPC6 inhibition. In a 12-week phase 2 trial in primary FSGS, the oral TRPC6 inhibitor
She also highlighted therapy targeting APOL1, which she believes could benefit patients of African descent who carry APOL1 high-risk alleles by protecting their podocytes. Vertex has
PARASOL Proteinuria Data Support Combination Therapy in FSGS
Weins said the PARASOL data reinforce the case for aggressive proteinuria control.
“We’ve learned a lot from the PARASOL data that just came out, that really any reduction in proteinuria is beneficial to those patients,” she said. “So we should do anything we can to reduce proteinuria.”
That points to multidrug regimens, with selection guided by disease activity and cause.
“A combination of drugs will likely be what we’re looking at,” Weins said. “But I think we can be more targeted specifically when we know what phase of disease we’re in and what cause is at play at the moment.”
Editor’s Note: Weins reports relevant disclosures with Vera Therapeutics, Sysmex, and Novartis.
References
Weins A, Radhakrishnan J, Tesar V. Advances in treatment and management of FSGS. Presented at: American Society of Nephrology Kidney Week 2026; October 22, 2026; Denver, CO.
Hillenbrand A. FDA approves sparsentan for focal segmental glomerulosclerosis. HCPLive. Published April 13, 2026. Accessed November 18, 2026.
https://www.hcplive.com/view/fda-approves-sparsentan-for-focal-segmental-glomerulosclerosis Trachtman H, Kretzler M, Gesualdo L, et al. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198. Lancet. 2026;407(10528):587-598. doi:10.1016/S0140-6736(25)02255-X
Hillenbrand A. Inaxaplin cuts proteinuria in broader APOL1 kidney disease population. HCPLive. Published September 23, 2026. Accessed November 18, 2026.
https://www.hcplive.com/view/inaxaplin-cuts-proteinuria-in-broader-apol1-kidney-disease-population
Related to this article








